IICT, Lee Pharma sign agreement for synthesis of 2-DG drug for COVID-19 patients
The Hindu
It has been found to help speed up recovery and reduce oxygen dependence and Dr. Reddy’s Laboratories has launched the drug in the form of sachets
The Indian Institute of Chemical Technology (IICT) in Hyderabad and city-based Lee Pharma, an integrated pharmaceutical company, have entered into a non-exclusive licensing agreement for the synthesis of 2-Deoxy-D-Glucose (2-DG) on Wednesday. 2-DG, developed by DRDO and Dr Reddy’s Laboratories, has received approval for use in Covid-19 patients. It has been found to help speed up recovery and reduce oxygen dependence and Dr. Reddy’s Laboratories has launched the drug in the form of sachets. Lee Pharma informed that they would file the application for getting the approval from Drug Controller General of India (DGCI), said a release.More Related News